Protara Therapeutics Reports P-II (ADVANCED-2) Trial on TARA-002 in BCG-Naïve Non-Muscle Invasive Bladder Cancer (NMIBC)

Shots:

• Protara has reported 12mos. data from Cohort A of the ongoing P-II (ADVANCED-2) trial assessing TARA-002 in pts with carcinoma in situ or CIS (± Ta/T1) NMIBC who are BCG-Unresponsive or BCG-Naïve; P-III (ADVANCED-3)trialin BCG-Naïve pts to initiatein H2’26
• The BCG-Naïve group (n=31), incl. 29 evaluable pts for efficacy, with 27 evaluable at 6mos. & 20 evaluable at 12mos. as of Apr 5, 2026. CR rates were 72.4% overall, 66.7% at 6mos., & 55% at 12mos.
• Among responders, the Kaplan-Meier estimated probability of maintaining CR for 6mos. was 73.1%, with 91.7% maintaining CR from 9-12mos., while 66.7% of re-induced pts achieved CR at 6mos; data were presented at AUA’26

Ref: Globenewswire |  Image: Protara Therapeutics  | Press Release

Related News: Resurge Therapeutics Presents Clinical Results on its Intraprostatic Drug Elution (IPDE) Platform for Benign Prostatic Hyperplasia (BPH) at AUA 2026

PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com